Vitamin D and Health

Study Methods Results Conclusions
Kim & Je (2014)
Prostate cancer
Gilbert et al (2011)
Ovarian cancer
Yin et al (2011)
Non melanoma skin cancer
Caini et al (2014)
Selection criteria:
Inclusion: original data from cohort/nested case-control
studies of vitamin D intake or blood 25(OH)D
concentrations; provided relative risks & confidence
intervals.
Exclusion: not reported.
Outcome measure: Breast cancer incidence or mortality
Selection criteria:
Inclusion: primary epidemiological data & either: serum
25(OH)D or 1,25(OH) 2 D) concentrations or dietary
and/or supplement vitamin D intake. 25(OH)D measured
prior to cancer diagnosis.
Exclusion: Animal or case studies. Chemotherapy also
included. Studies on vit D & prostate cancer survival.
Outcome measure: Prostate cancer
Selection criteria:
Inclusion: Original longitudinal human studies.
Exclusion: Reviews, ecological & case control studies;
only vitamin D intake reported; only ovarian cancer
mortality assessed.
Outcome measure Ovarian cancer incidence & mortality.
Selection criteria:
Inclusion: RCTs, case-control, nested case control, cohort
studies examining association between vitamin D intake/
25(OH)D concentration & cutaneous melanoma/non
melanoma skin cancer risk which included measure of
relative risk with 95% CI or another measure of statistical
uncertainty & measure of tumour thickness.
Exclusion: Ecological studies, case reports, reviews,
editorials.
Outcome measure
Cutaneous melanoma & non melanoma skin cancer.
Breast cancer risk (13 nested case control/1 cohort study; 9526 cases)
25(OH)D concentration (nmol/L): Highest (>77.4) vs lowest (72.6) vs lowest ( 72.6 vs < 52.4 nmol/L
was significantly associated with
better breast cancer survival.
No association between 25(OH)D
and total and aggressive prostate
cancer risk.
No significant association between
25(OH)D and ovarian cancer risk.
No association between 25(OH)D
& cutaneous melanoma risk.
Higher 25(OH)D concentration
associated with significant
increase in basal cell skin cancer &
non melanoma skin cancer risk.
219